JP2012502649A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012502649A5 JP2012502649A5 JP2011527406A JP2011527406A JP2012502649A5 JP 2012502649 A5 JP2012502649 A5 JP 2012502649A5 JP 2011527406 A JP2011527406 A JP 2011527406A JP 2011527406 A JP2011527406 A JP 2011527406A JP 2012502649 A5 JP2012502649 A5 JP 2012502649A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- seq
- amino acid
- cdr1
- cdr2
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 101100112922 Candida albicans CDR3 gene Proteins 0.000 claims 10
- 125000003275 alpha amino acid group Chemical group 0.000 claims 9
- 210000004602 germ cell Anatomy 0.000 claims 8
- 125000000539 amino acid group Chemical group 0.000 claims 6
- 238000006467 substitution reaction Methods 0.000 claims 6
- 230000000694 effects Effects 0.000 claims 3
- 230000001747 exhibiting effect Effects 0.000 claims 2
- 241000124008 Mammalia Species 0.000 claims 1
- 206010027476 Metastases Diseases 0.000 claims 1
- 101710143123 Mothers against decapentaplegic homolog 2 Proteins 0.000 claims 1
- 102000057208 Smad2 Human genes 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 230000001772 anti-angiogenic effect Effects 0.000 claims 1
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 230000004663 cell proliferation Effects 0.000 claims 1
- 230000008878 coupling Effects 0.000 claims 1
- 238000010168 coupling process Methods 0.000 claims 1
- 238000005859 coupling reaction Methods 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 230000009401 metastasis Effects 0.000 claims 1
- 230000026731 phosphorylation Effects 0.000 claims 1
- 238000006366 phosphorylation reaction Methods 0.000 claims 1
- 230000004614 tumor growth Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US9868508P | 2008-09-19 | 2008-09-19 | |
| US61/098,685 | 2008-09-19 | ||
| PCT/GB2009/051216 WO2010032059A2 (en) | 2008-09-19 | 2009-09-18 | Targeted binding agents directed to cd105 and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2012502649A JP2012502649A (ja) | 2012-02-02 |
| JP2012502649A5 true JP2012502649A5 (enExample) | 2012-11-01 |
Family
ID=41263674
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011527406A Withdrawn JP2012502649A (ja) | 2008-09-19 | 2009-09-18 | Ｃｄ１０５を対象とする標的結合剤およびその使用 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20100196398A1 (enExample) |
| EP (1) | EP2344541A2 (enExample) |
| JP (1) | JP2012502649A (enExample) |
| KR (1) | KR20110057245A (enExample) |
| CN (1) | CN102388067A (enExample) |
| AU (1) | AU2009294414A1 (enExample) |
| BR (1) | BRPI0918555A2 (enExample) |
| CA (1) | CA2737667A1 (enExample) |
| WO (1) | WO2010032059A2 (enExample) |
Families Citing this family (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101531400B1 (ko) | 2003-06-27 | 2015-06-26 | 암젠 프레몬트 인코포레이티드 | 상피 성장 인자 수용체의 결실 돌연변이체 지향 항체 및 그용도 |
| WO2008027986A2 (en) | 2006-09-01 | 2008-03-06 | Therapeutic Human Polyclonals, Inc. | Enhanced expression of human or humanized immunoglobulin in non-human transgenic animals |
| HRP20140049T1 (hr) | 2007-01-05 | 2014-02-28 | University Of Zürich | Anti beta-amiloid antitijela i njihova upotreba |
| WO2010069603A1 (en) | 2008-12-19 | 2010-06-24 | Neurimmune Therapeutics Ag | Human anti-alpha-synuclein autoantibodies |
| US8221753B2 (en) | 2009-09-30 | 2012-07-17 | Tracon Pharmaceuticals, Inc. | Endoglin antibodies |
| UA109888C2 (uk) | 2009-12-07 | 2015-10-26 | ІЗОЛЬОВАНЕ АНТИТІЛО АБО ЙОГО ФРАГМЕНТ, ЩО ЗВ'ЯЗУЄТЬСЯ З β-КЛОТО, РЕЦЕПТОРАМИ FGF І ЇХНІМИ КОМПЛЕКСАМИ | |
| CN103237901B (zh) | 2010-03-01 | 2016-08-03 | 卡里斯生命科学瑞士控股有限责任公司 | 用于治疗诊断的生物标志物 |
| CA2795776A1 (en) | 2010-04-06 | 2011-10-13 | Caris Life Sciences Luxembourg Holdings, S.A.R.L. | Circulating biomarkers for disease |
| TWI636993B (zh) * | 2010-10-27 | 2018-10-01 | 安美基公司 | Ｄｋｋ１抗體及使用方法 |
| JP2014508523A (ja) * | 2011-02-23 | 2014-04-10 | ヘルス リサーチ インコーポレイテッド | 抗エンドグリン抗体及び新規ヒト／マウスキメラエンドグリンを発現するノックインマウス |
| JP2014509588A (ja) * | 2011-03-01 | 2014-04-21 | アムジエン・インコーポレーテツド | 二特異性結合剤 |
| US9255595B2 (en) * | 2011-04-29 | 2016-02-09 | Bae Systems Information And Electronic Systems Integration Inc. | Optical dome bezel |
| LT2723379T (lt) * | 2011-06-23 | 2018-10-25 | Biogen International Neuroscience Gmbh | Anti-alfa sinukleiną rišančios molekulės |
| US20130156766A1 (en) * | 2011-11-15 | 2013-06-20 | Allergan, Inc. | Treatment of dry age related macular degeneration |
| UA115789C2 (uk) * | 2012-09-05 | 2017-12-26 | Трейкон Фармасутікалз, Інк. | Композиція антитіла до cd105 та її застосування |
| US9926375B2 (en) | 2014-11-12 | 2018-03-27 | Tracon Pharmaceuticals, Inc. | Anti-endoglin antibodies and uses thereof |
| CA2966905A1 (en) | 2014-11-12 | 2016-05-19 | Tracon Pharmaceuticals, Inc. | Anti-endoglin antibodies and uses thereof |
| MA41115A (fr) | 2014-12-02 | 2017-10-10 | Biogen Int Neuroscience Gmbh | Procédé de traitement de la maladie d'alzheimer |
| CN105821029A (zh) * | 2015-01-04 | 2016-08-03 | 彭霞 | 异源融合基因修饰的癌细胞/树突状细胞融合肿瘤疫苗及其制备方法 |
| CN113862300A (zh) * | 2015-10-29 | 2021-12-31 | 豪夫迈·罗氏有限公司 | 具有共同轻链的转基因兔 |
| CN106928355B (zh) * | 2015-12-30 | 2020-09-29 | 广西医科大学 | 一种CD105纳米抗体Nb184 |
| CN106928359B (zh) * | 2015-12-30 | 2020-10-13 | 广西医科大学 | 一种CD105纳米抗体Nb59 |
| US10729771B2 (en) | 2016-02-10 | 2020-08-04 | Rutgers, The State University Of New Jersey | Anti-LAM and anti-PIM6/LAM monoclonal antibodies for diagnosis and treatment of Mycobacterium tuberculosis infections |
| CN117205321A (zh) * | 2016-06-14 | 2023-12-12 | 西达-赛奈医疗中心 | 通过内皮糖蛋白拮抗作用使肿瘤对疗法敏感 |
| SI3672631T1 (sl) | 2017-08-22 | 2023-06-30 | Biogen Ma Inc. | Farmacevtski sestavki, ki vsebujejo protitelesa proti beta amiloidu |
| CN108912212B (zh) * | 2018-06-28 | 2019-08-30 | 中山大学附属口腔医院 | 一种与cd105特异性结合的多肽及其应用 |
| WO2020106461A2 (en) * | 2018-11-08 | 2020-05-28 | Celldex Therapeutics, Inc. | Anti-mertk antibodies and methods of use thereof |
| KR20210095781A (ko) | 2020-01-24 | 2021-08-03 | 주식회사 에이프릴바이오 | 항원결합 단편 및 생리활성 이펙터 모이어티로 구성된 융합 컨스트럭트를 포함하는 다중결합항체 및 이를 포함하는 약학조성물 |
| WO2021206636A1 (en) * | 2020-04-07 | 2021-10-14 | Agency For Science, Technology And Research | ANTIGEN-BINDING PROTEIN TO SARS-CoV-2 |
| CN112426526B (zh) * | 2021-01-25 | 2021-04-06 | 北京达熙生物科技有限公司 | 一种nk细胞的制备方法及其在治疗癌症中的应用 |
| CN112876538B (zh) * | 2021-02-04 | 2022-09-30 | 福建医科大学 | 靶向新生血管标记物cd105的多肽及其应用 |
| WO2022187710A1 (en) * | 2021-03-05 | 2022-09-09 | Atreca, Inc. | Epha2 antibodies |
| EP4463135A2 (en) | 2022-01-10 | 2024-11-20 | Sana Biotechnology, Inc. | Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses |
| EP4469479A2 (en) * | 2022-01-24 | 2024-12-04 | Genovac Antibody Discovery LLC | Anti-alk1 antibodies and methods of using the same |
| EP4572772A1 (en) | 2022-08-17 | 2025-06-25 | Capstan Therapeutics, Inc. | Conditioning for in vivo immune cell engineering |
| EP4602174A1 (en) | 2022-10-13 | 2025-08-20 | Sana Biotechnology, Inc. | Viral particles targeting hematopoietic stem cells |
| EP4627096A1 (en) | 2022-12-02 | 2025-10-08 | Sana Biotechnology, Inc. | Lipid particles with cofusogens and methods of producing and using the same |
| AU2024274792A1 (en) | 2023-05-23 | 2025-10-23 | Sana Biotechnology, Inc. | Tandem fusogens and related lipid particles |
| US12311033B2 (en) | 2023-05-31 | 2025-05-27 | Capstan Therapeutics, Inc. | Lipid nanoparticle formulations and compositions |
| WO2025045032A1 (zh) * | 2023-08-29 | 2025-03-06 | 应世生物科技(南京)有限公司 | 一种靶向cd105的抗体或其抗原结合片段及其应用 |
| US20250127728A1 (en) | 2023-10-05 | 2025-04-24 | Capstan Therapeutics, Inc. | Constrained Ionizable Cationic Lipids and Lipid Nanoparticles |
| WO2025076113A1 (en) | 2023-10-05 | 2025-04-10 | Capstan Therapeutics, Inc. | Ionizable cationic lipids with conserved spacing and lipid nanoparticles |
| WO2025149667A1 (en) | 2024-01-12 | 2025-07-17 | Pheon Therapeutics Ltd | Antibody drug conjugates and uses thereof |
| WO2025184529A1 (en) | 2024-03-01 | 2025-09-04 | Sana Biotechnology, Inc. | Viral particles with fusogen display and related compositions and methods |
| WO2025217454A2 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Ionizable cationic lipids and lipid nanoparticles |
| WO2025217452A1 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Constrained ionizable cationic lipids and lipid nanoparticles |
| TWI882851B (zh) * | 2024-06-27 | 2025-05-01 | 蔡政育 | 基於專利技術元素整合之專利分析系統及其方法 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6190660B1 (en) * | 1996-05-31 | 2001-02-20 | Health Research, Inc. | Anti-endoglin monoclonal antibodies and their use in antiangiogenic therapy |
| US6323334B1 (en) * | 1999-09-24 | 2001-11-27 | Millennium Pharmaceuticals, Inc. | Nucleic acid molecules encoding a 103 gene product and uses therefor |
| EP2275449B1 (en) * | 2000-06-16 | 2016-09-28 | Human Genome Sciences, Inc. | Antibodies that immunospecifically bind to BLyS |
-
2009
- 2009-09-18 WO PCT/GB2009/051216 patent/WO2010032059A2/en not_active Ceased
- 2009-09-18 EP EP09785666A patent/EP2344541A2/en not_active Withdrawn
- 2009-09-18 CN CN2009801467390A patent/CN102388067A/zh active Pending
- 2009-09-18 KR KR1020117008833A patent/KR20110057245A/ko not_active Withdrawn
- 2009-09-18 AU AU2009294414A patent/AU2009294414A1/en not_active Abandoned
- 2009-09-18 JP JP2011527406A patent/JP2012502649A/ja not_active Withdrawn
- 2009-09-18 BR BRPI0918555A patent/BRPI0918555A2/pt not_active IP Right Cessation
- 2009-09-18 US US12/562,533 patent/US20100196398A1/en not_active Abandoned
- 2009-09-18 CA CA2737667A patent/CA2737667A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012502649A5 (enExample) | ||
| JP2012525829A5 (enExample) | ||
| WO2010095031A3 (en) | Humanized antibodies that bind to cd19 and their uses | |
| JP2013198490A5 (enExample) | ||
| JP2014526898A5 (enExample) | ||
| JP2016512551A5 (enExample) | ||
| JP2014534242A5 (enExample) | ||
| JP2013538057A5 (enExample) | ||
| JP2011526480A5 (enExample) | ||
| JP2015504421A5 (enExample) | ||
| AU2016204274A1 (en) | Antibodies that bind to OX40 and their uses | |
| JP2017052784A5 (enExample) | ||
| JP2014205674A5 (enExample) | ||
| JP2020504101A5 (enExample) | ||
| JP2013544756A5 (enExample) | ||
| JP2009225799A5 (enExample) | ||
| JP2015504306A5 (enExample) | ||
| RU2020129387A (ru) | Антитела к pd-1 собак | |
| RU2017128882A (ru) | Антитела к биотину и способы их применения | |
| JP2013517330A5 (enExample) | ||
| JP2013545455A5 (enExample) | ||
| JP2010515717A5 (enExample) | ||
| JP2011517447A5 (enExample) | ||
| RU2012142230A (ru) | Антитела против csf-1r человека и их применение | |
| JP2012531922A5 (ja) | Ｔｏｌｌ様受容体２へのヒト化抗体またはその抗原結合部位 |